Posted by Michael Wonder on 22 Apr 2020
Wockhardt receives US FDA qualified infectious disease product designation for WCK 6777, a first ever once-a-day β-lactam enhancer class antibiotic
20 April 2020 - WCK 6777 is a once-a-day combination antibiotic based on Wockhardt’s NCE zidebactam, which imparts WCK 6777 novel mechanism of β-lactam enhancer.
Being a once-a-day drug, WCK 6777 would be the first ever antibiotic facilitating the treatment of multi-drug resistant infections in out-patient settings. Wockhardt’s other zidebactam-based product, WCK 5222, has received US FDA’s nod for global Phase 3 clinical trial.
WCK 6777 for injection has been awarded a qualified infectious disease product for the following indications:
- Treatment of complicated urinary tract infections, including pyelonephritis
- Treatment of complicated intra-abdominal infections
